Selected research
Industry Research
Nuclear Medicine Imaging Agents Industry Research Report 2026
Market perspective
The global Nuclear Medicine Imaging Agents market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Nuclear Medicine Imaging Agents is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Nuclear Medicine Imaging Agents is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Nuclear Medicine Imaging Agents is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Nuclear Medicine Imaging Agents include Jubilant Pharma Limited, Foshan Rui Diao Pharmaceutical, Yantai Dongcheng, Navidea, Mallinckrodt, Lantheus, Guerbet, GE HealthCare and Eli Lilly and Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Nuclear Medicine Imaging Agents market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nuclear Medicine Imaging Agents Market by Company
Jubilant Pharma Limited
Foshan Rui Diao Pharmaceutical
Yantai Dongcheng
Navidea
Mallinckrodt
Lantheus
Guerbet
GE HealthCare
Eli Lilly and Company
Cardinal Health
Bracco Diagnostic
Blue Earth Diagnostics
Bayer AG
Abx Advanced Biochemical
Nuclear Medicine Imaging Agents Segment by Type
Nitrogen 13 Labeling
Technetium 99 Labeling
Fluorine 18 Labeling
Carbon 11 Labeling
Oxygen 15 Labeling
Others
Nuclear Medicine Imaging Agents Segment by Application
Clinical Stage
Early Diagnosis
Treatment Evaluation
Nuclear Medicine Imaging Agents Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine Imaging Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine Imaging Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine Imaging Agents.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Nuclear Medicine Imaging Agents manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Nuclear Medicine Imaging Agents by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Nuclear Medicine Imaging Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Nitrogen 13 Labeling
- Technetium 99 Labeling
- Fluorine 18 Labeling
- Carbon 11 Labeling
- Oxygen 15 Labeling
- Others
Applications
- Clinical Stage
- Early Diagnosis
- Treatment Evaluation
Companies covered
- Jubilant Pharma Limited
- Foshan Rui Diao Pharmaceutical
- Yantai Dongcheng
- Navidea
- Mallinckrodt
- Lantheus
- Guerbet
- GE HealthCare
- Eli Lilly and Company
- Cardinal Health
- Bracco Diagnostic
- Blue Earth Diagnostics
- Bayer AG
- Abx Advanced Biochemical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Nuclear Medicine Imaging Agents Market Size (2021-2032)
- 2.2.2 Global Nuclear Medicine Imaging Agents Sales (2021-2032)
- 2.2.3 Global Nuclear Medicine Imaging Agents Market Average Price (2021-2032)
- 2.3 Nuclear Medicine Imaging Agents by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Nitrogen 13 Labeling
- 2.3.3 Technetium 99 Labeling
- 2.3.4 Fluorine 18 Labeling
- 2.3.5 Carbon 11 Labeling
- 2.3.6 Oxygen 15 Labeling
- 2.3.7 Others
- 2.4 Nuclear Medicine Imaging Agents by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinical Stage
- 2.4.3 Early Diagnosis
- 2.4.4 Treatment Evaluation
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Nuclear Medicine Imaging Agents Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Nuclear Medicine Imaging Agents Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Nuclear Medicine Imaging Agents Revenue of Manufacturers (2021-2026)
- 3.4 Global Nuclear Medicine Imaging Agents Average Price by Manufacturers (2021-2026)
- 3.5 Global Nuclear Medicine Imaging Agents Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Nuclear Medicine Imaging Agents, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Nuclear Medicine Imaging Agents, Product Type & Application
- 3.8 Global Manufacturers of Nuclear Medicine Imaging Agents, Established Date
- 3.9 Global Nuclear Medicine Imaging Agents Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Jubilant Pharma Limited
- 4.1.1 Jubilant Pharma Limited Company Information
- 4.1.2 Jubilant Pharma Limited Business Overview
- 4.1.3 Jubilant Pharma Limited Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Jubilant Pharma Limited Nuclear Medicine Imaging Agents Product Portfolio
- 4.1.5 Jubilant Pharma Limited Recent Developments
- 4.2 Foshan Rui Diao Pharmaceutical
- 4.2.1 Foshan Rui Diao Pharmaceutical Company Information
- 4.2.2 Foshan Rui Diao Pharmaceutical Business Overview
- 4.2.3 Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Product Portfolio
- 4.2.5 Foshan Rui Diao Pharmaceutical Recent Developments
- 4.3 Yantai Dongcheng
- 4.3.1 Yantai Dongcheng Company Information
- 4.3.2 Yantai Dongcheng Business Overview
- 4.3.3 Yantai Dongcheng Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Yantai Dongcheng Nuclear Medicine Imaging Agents Product Portfolio
- 4.3.5 Yantai Dongcheng Recent Developments
- 4.4 Navidea
- 4.4.1 Navidea Company Information
- 4.4.2 Navidea Business Overview
- 4.4.3 Navidea Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Navidea Nuclear Medicine Imaging Agents Product Portfolio
- 4.4.5 Navidea Recent Developments
- 4.5 Mallinckrodt
- 4.5.1 Mallinckrodt Company Information
- 4.5.2 Mallinckrodt Business Overview
- 4.5.3 Mallinckrodt Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mallinckrodt Nuclear Medicine Imaging Agents Product Portfolio
- 4.5.5 Mallinckrodt Recent Developments
- 4.6 Lantheus
- 4.6.1 Lantheus Company Information
- 4.6.2 Lantheus Business Overview
- 4.6.3 Lantheus Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Lantheus Nuclear Medicine Imaging Agents Product Portfolio
- 4.6.5 Lantheus Recent Developments
- 4.7 Guerbet
- 4.7.1 Guerbet Company Information
- 4.7.2 Guerbet Business Overview
- 4.7.3 Guerbet Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Guerbet Nuclear Medicine Imaging Agents Product Portfolio
- 4.7.5 Guerbet Recent Developments
- 4.8 GE HealthCare
- 4.8.1 GE HealthCare Company Information
- 4.8.2 GE HealthCare Business Overview
- 4.8.3 GE HealthCare Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GE HealthCare Nuclear Medicine Imaging Agents Product Portfolio
- 4.8.5 GE HealthCare Recent Developments
- 4.9 Eli Lilly and Company
- 4.9.1 Eli Lilly and Company Company Information
- 4.9.2 Eli Lilly and Company Business Overview
- 4.9.3 Eli Lilly and Company Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Eli Lilly and Company Nuclear Medicine Imaging Agents Product Portfolio
- 4.9.5 Eli Lilly and Company Recent Developments
- 4.10 Cardinal Health
- 4.10.1 Cardinal Health Company Information
- 4.10.2 Cardinal Health Business Overview
- 4.10.3 Cardinal Health Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Cardinal Health Nuclear Medicine Imaging Agents Product Portfolio
- 4.10.5 Cardinal Health Recent Developments
- 4.11 Bracco Diagnostic
- 4.11.1 Bracco Diagnostic Company Information
- 4.11.2 Bracco Diagnostic Business Overview
- 4.11.3 Bracco Diagnostic Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Bracco Diagnostic Nuclear Medicine Imaging Agents Product Portfolio
- 4.11.5 Bracco Diagnostic Recent Developments
- 4.12 Blue Earth Diagnostics
- 4.12.1 Blue Earth Diagnostics Company Information
- 4.12.2 Blue Earth Diagnostics Business Overview
- 4.12.3 Blue Earth Diagnostics Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Blue Earth Diagnostics Nuclear Medicine Imaging Agents Product Portfolio
- 4.12.5 Blue Earth Diagnostics Recent Developments
- 4.13 Bayer AG
- 4.13.1 Bayer AG Company Information
- 4.13.2 Bayer AG Business Overview
- 4.13.3 Bayer AG Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Bayer AG Nuclear Medicine Imaging Agents Product Portfolio
- 4.13.5 Bayer AG Recent Developments
- 4.14 Abx Advanced Biochemical
- 4.14.1 Abx Advanced Biochemical Company Information
- 4.14.2 Abx Advanced Biochemical Business Overview
- 4.14.3 Abx Advanced Biochemical Nuclear Medicine Imaging Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Abx Advanced Biochemical Nuclear Medicine Imaging Agents Product Portfolio
- 4.14.5 Abx Advanced Biochemical Recent Developments
5 Global Nuclear Medicine Imaging Agents Market Scenario by Region
- 5.1 Global Nuclear Medicine Imaging Agents Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Nuclear Medicine Imaging Agents Sales by Region: 2021-2032
- 5.2.1 Global Nuclear Medicine Imaging Agents Sales by Region: 2021-2026
- 5.2.2 Global Nuclear Medicine Imaging Agents Sales by Region: 2027-2032
- 5.3 Global Nuclear Medicine Imaging Agents Revenue by Region: 2021-2032
- 5.3.1 Global Nuclear Medicine Imaging Agents Revenue by Region: 2021-2026
- 5.3.2 Global Nuclear Medicine Imaging Agents Revenue by Region: 2027-2032
- 5.4 North America Nuclear Medicine Imaging Agents Market Facts & Figures by Country
- 5.4.1 North America Nuclear Medicine Imaging Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Nuclear Medicine Imaging Agents Sales by Country (2021-2032)
- 5.4.3 North America Nuclear Medicine Imaging Agents Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Nuclear Medicine Imaging Agents Market Facts & Figures by Country
- 5.5.1 Europe Nuclear Medicine Imaging Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Nuclear Medicine Imaging Agents Sales by Country (2021-2032)
- 5.5.3 Europe Nuclear Medicine Imaging Agents Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Nuclear Medicine Imaging Agents Market Facts & Figures by Country
- 5.6.1 Asia Pacific Nuclear Medicine Imaging Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Nuclear Medicine Imaging Agents Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Nuclear Medicine Imaging Agents Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Nuclear Medicine Imaging Agents Market Facts & Figures by Country
- 5.7.1 South America Nuclear Medicine Imaging Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Nuclear Medicine Imaging Agents Sales by Country (2021-2032)
- 5.7.3 South America Nuclear Medicine Imaging Agents Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Nuclear Medicine Imaging Agents Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Nuclear Medicine Imaging Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Nuclear Medicine Imaging Agents Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Nuclear Medicine Imaging Agents Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Nuclear Medicine Imaging Agents Sales by Type (2021-2032)
- 6.1.1 Global Nuclear Medicine Imaging Agents Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Nuclear Medicine Imaging Agents Sales Market Share by Type (2021-2032)
- 6.2 Global Nuclear Medicine Imaging Agents Revenue by Type (2021-2032)
- 6.2.1 Global Nuclear Medicine Imaging Agents Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Nuclear Medicine Imaging Agents Revenue Market Share by Type (2021-2032)
- 6.3 Global Nuclear Medicine Imaging Agents Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Nuclear Medicine Imaging Agents Sales by Application (2021-2032)
- 7.1.1 Global Nuclear Medicine Imaging Agents Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Nuclear Medicine Imaging Agents Sales Market Share by Application (2021-2032)
- 7.2 Global Nuclear Medicine Imaging Agents Revenue by Application (2021-2032)
- 7.2.1 Global Nuclear Medicine Imaging Agents Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Nuclear Medicine Imaging Agents Revenue Market Share by Application (2021-2032)
- 7.3 Global Nuclear Medicine Imaging Agents Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Nuclear Medicine Imaging Agents Value Chain Analysis
- 8.1.1 Nuclear Medicine Imaging Agents Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Nuclear Medicine Imaging Agents Production Mode & Process
- 8.2 Nuclear Medicine Imaging Agents Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Nuclear Medicine Imaging Agents Distributors
- 8.2.3 Nuclear Medicine Imaging Agents Customers
9 Global Nuclear Medicine Imaging Agents Analyzing Market Dynamics
- 9.1 Nuclear Medicine Imaging Agents Industry Trends
- 9.2 Nuclear Medicine Imaging Agents Industry Drivers
- 9.3 Nuclear Medicine Imaging Agents Industry Opportunities and Challenges
- 9.4 Nuclear Medicine Imaging Agents Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst